Study may open new options for younger women with breast cancer

June 1, 2014 11:35 AM

7 0

CHICAGO (Reuters) - The estrogen-blocking drug Aromasin worked better than the long-standing therapy tamoxifen at keeping cancers from returning in younger women with early stage breast cancer, a finding that may change the way the patients are treated, U.S. researchers said on Sunday.

Aromasin, a drug developed by Pfizer Inc that is sold generically as exemestane, is in a class of treatments called aromatase inhibitors that are typically used in post-menopausal women with low levels of estrogen.

Also read: From Clinton and Trump, harshly negative arguments with two weeks to go

Read more

To category page